Q11.DU Amaroq Ltd.
- Market cap
- EUR 557M
- P/E
- 119.0x
- P/B
- 2.79x
- ROE
- -7.6%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is Q11.DU undervalued?
Graham numberThe Graham number of Amaroq Ltd. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amaroq Ltd. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-7.6%), below 10%.
ROA 1/1
Return on assets (-6.0%) is above the industry median (-11.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-1,765.7%) is below the industry median (-12.7%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.5 years of the current cash burn.
PE vs Market 0/1
PE (119.0x) is above the market median (18.2x).
PE vs Industry 0/1
PE (119.0x) is above the industry median (7.9x).
PBV 0/1
Price to book (2.8x) is above the industry median (2.7x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 332.3, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Amaroq Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amaroq Ltd.
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.
Full company profileAmaroq Ltd. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amaroq Ltd. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 21.7M |
| Gross Profit | -90.2K | - | - | - | - |
| Operating Income | -24.0M | -22.9M | -22.8M | -21.0M | -20.5M |
| EBITDA | -24.3M | -21.0M | -20.9K | -22.5M | -19.6M |
| Net Income | -24.7M | -21.9M | -834K | -23.5M | -20.5M |
| EPS | -0.14 | -0.08 | 0.00 | -0.06 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 42.8M | 65.1M | 107M | 256M | 339M |
| Total Liabilities | 2.81M | 1.87M | 43.0M | 54.8M | 69.8M |
| Shareholders' Equity | 40.0M | 63.2M | 64.3M | 201M | 269M |
| Cash & Short-term Investments | 27.3M | 50.1M | 21.0M | 45.2M | 55.3M |
| Cash Flow | |||||
| Operating Cash Flow | -22.3M | -20.9M | -34.2M | -6.03M | -31.3M |
| Capital Expenditure | 11.9M | 325K | 24.3M | 111M | 77.5M |
| Free Cash Flow | -34.2M | -21.2M | -58.5M | -117M | -109M |
| Ratios | |||||
| ROE | -61.8% | -34.6% | -1.3% | -11.7% | -7.6% |
| ROA | -57.7% | -33.6% | -0.8% | -9.2% | -6.0% |
| Net Profit Margin | - | - | - | - | -94.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Amaroq Ltd. dividends
Amaroq Ltd. has not paid dividends in the last 4 fiscal years.
Who owns Amaroq Ltd.
Ownership data of Amaroq Ltd. is not available yet.
Amaroq Ltd. company profile
- Company name
- Amaroq Ltd.
- Ticker
- Q11.DU
- ISIN
- CA02311U1030
- Exchange
- Dusseldorf Exchange
- Sector
- Basic Materials
- Industry
- Gold
- Fiscal year end
- December
- Address
- Flensburger Straße 18, Pinneberg, Germany, 25421
- Phone
- 49 4101 809960
- Website
- viromed-medical-ag.de
About Amaroq Ltd.
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.